Cardiac function after eight hour storage by using polyethylene glycol hemoglobin versus crystalloid perfusion.
Efforts to extend myocardial preservation for transplantation by crystalloid perfusion have been limited by edema and compromised function. We hypothesized that hypothermic perfusion preservation with a polyethylene glycol (PEG) conjugated hemoglobin solution may extend preservation times. The purpose of this study was to compare cardiac function after continuous perfusion by using a hypocalcemic, normokalemic crystalloid perfusate with and without the addition of PEG-hemoglobin (Hb). The hearts of 20 anesthetized and ventilated New Zealand White rabbits were harvested after cold cardioplegic arrest. Group I (n = 10) hearts were continuously perfused with a hypocalcemic, normokalemic 3% bovine PEG-Hb solution at 20 degrees C and 30 mm Hg for 8 hours. Group II (n = 10) hearts were continuously perfused with an identical crystalloid solution without PEG-Hb for 8 hours under the same conditions as group I hearts. Cardiac function was measured with a left ventricular force transducer after transfer to a standard crystalloid Langendorff circuit at 37 degrees C and an aortic root pressure of 59 mm Hg. After 8 hours of perfusion preservation, heart rate was similar for groups I and II (p = not significant [NS]). Coronary blood flow after and during preservation was similar between PEG-Hb and crystalloid preserved hearts (p = NS). Left ventricular developed pressure, peak dP/dt, and peak -dP/dt were superior in hearts preserved with PEG-Hb. Percent water of total ventricular weight was 82.0% for group I and 81.6% for group II (p = NS). Continuous perfusion preservation of rabbit hearts for 8 hours with a hypocalcemic normokalemic PEG-Hb based solution at 30 mm Hg and 20 degrees C yields left ventricular function that is superior to perfusion with a similar crystalloid solution without PEG-Hb, despite similar myocardial edema and coronary flow. Extended cardiac perfusion preservation with this PEG-Hb based solution deserves further study, including comparison with traditional cardioplegic preservation solutions.
Serna
D L
DL
Department of Pharmacology, UC Irvine Medical Center, Orange, California 92868, USA.
Powell
L L
LL
Kahwaji
C
C
Wallace
W C
WC
West
J
J
Cogert
G
G
Smulowitz
P
P
Steward
E
E
Purdy
R E
RE
Milliken
J C
JC
D000818:Animals; D000077324:Crystalloid Solutions; D006321:Heart / Q000502:physiology*; D006454:Hemoglobins / Q000494:pharmacology*; D007552:Isotonic Solutions; D008297:Male; D009200:Myocardial Contraction; D009926:Organ Preservation; D010477:Perfusion; D010952:Plasma Substitutes / Q000494:pharmacology*; D011092:Polyethylene Glycols / Q000494:pharmacology*; D011817:Rabbits; D016277:Ventricular Function, Left
D000077324:Crystalloid Solutions; D006454:Hemoglobins; D007552:Isotonic Solutions; C109960:PEG-hemoglobin; D010952:Plasma Substitutes; D011092:Polyethylene Glycols